Switzerland is one of Europe’s most scientifically advanced clinical research environments. The country is home to a disproportionate share of global pharmaceutical and biotech headquarters – including Roche, Novartis, and Lonza – and its academic hospitals rank among the world’s most cited research institutions. Switzerland offers exceptional investigator expertise, outstanding Phase I units, and a strong translational research tradition, particularly in oncology, rare diseases, and precision medicine.
However, sponsors must understand a critical regulatory distinction: Switzerland is not a member of the EU or EEA, and does not participate in CTIS or the EU Clinical Trials Regulation (EU CTR, Regulation EU 536/2014). Clinical trials in Switzerland are governed entirely by Swiss national law – the Human Research Act (HRA, SR 810.30) and the Clinical Trials Ordinance (ClinO, SR 810.305) – and are approved through Swiss-specific processes involving Swissmedic and the cantonal ethics committee system coordinated by swissethics. Sponsors adding Switzerland to an EU programme must manage it as a fully separate regulatory track.
Switzerland is among the most expensive countries in Europe for clinical research, and the added complexity of a separate non-EU regulatory process means that sponsors must have a clear scientific or strategic reason to justify its inclusion. When that justification exists – world-class investigator, unique patient population, Phase I capability, or proximity to a key pharma partner – Switzerland adds exceptional value.
| Metric | Switzerland |
| Competent Authority | Swissmedic (Swiss Agency for Therapeutic Products) |
| Ethics Review | Cantonal ethics committees (coordinated by swissethics) |
| Approval Timeline | ~30–40 days (Swissmedic) + ~30–45 days (cantonal EC, parallel) |
| Population | ~8.7 million |
| Strengths | Oncology, rare diseases, precision medicine, Phase I; pharma HQ ecosystem |
Switzerland attracts sponsors for reasons of investigator quality and pharma ecosystem, not regulatory simplicity or patient volume. Sponsors typically include Switzerland when:
Switzerland is not a cost-efficient choice, and the non-EU regulatory pathway adds material complexity. Sponsors who include Switzerland purely for geographic coverage without a specific scientific or strategic rationale will incur unnecessary cost and administrative burden.
Switzerland operates under its own national regulatory framework, which is entirely separate from the EU CTR. The legal basis is the Human Research Act (HRA, Humanforschungsgesetz, SR 810.30) and the Clinical Trials Ordinance (ClinO, Verordnung über klinische Versuche, SR 810.305), which together govern all clinical research involving human participants in Switzerland.
The competent authority is Swissmedic (Swiss Agency for Therapeutic Products). Swiss clinical trials are classified into three categories that affect the procedure and timelines:
Ethics review is conducted by the cantonal ethics committees, coordinated nationally by swissethics. For multi-site trials involving cantons with different ethics committees, a lead cantonal committee is designated and other participating cantonal committees conduct a streamlined review. This is similar in concept to the EU CTR’s multi-state process, but operates entirely outside the EU framework.
Sponsors must note that Switzerland has specific requirements regarding the sponsor’s legal address and responsibility. Non-Swiss sponsors typically require a Swiss sponsor representative or trial site to assume regulatory responsibility. Swiss GCP requirements are aligned with ICH E6 but have Swiss-specific adaptations that must be reflected in the clinical trial agreement and monitoring approach.
Switzerland’s regulatory and ethics review timelines are competitive for a non-EU country. The parallel Swissmedic and cantonal ethics review process is efficient for well-prepared Category B applications. Typical timelines:
| Step | Estimated Timeline |
|---|---|
| BASEC submission and validation | 1–5 working days |
| Swissmedic review (Cat. B) | ~30–40 days |
| Cantonal ethics committee review | ~30–45 days (parallel) |
| Query response period (if applicable) | 10–30 days (clock stopped) |
| Site contract and budget negotiation | 6–12 weeks |
| Estimated total from submission to first patient | ~3–5 months |
The Swiss process is genuinely efficient when dossiers are complete and well-prepared. Swiss site contracting at the major university hospitals (USZ, USB, Inselspital, CHUV, HUG) is generally professional and organised, reflecting the institutional experience with international industry-sponsored trials.
Switzerland’s five university hospital centres are the primary trial sites, with strong Phase I units and internationally recognised investigators:
Switzerland’s patient pool is limited by its population of approximately 8.7 million. However, Swiss academic hospitals attract highly complex cases through their international reputations and specialist referral networks. For Phase I and early Phase II oncology trials in particular, Swiss sites can enrol treatment-experienced, heavily pre-treated patients through their advanced oncology services.
For rare diseases, Switzerland’s university hospitals maintain specialist registries and have ERN-adjacent relationships despite not being EU members. Patient identification at Swiss rare disease centres can be efficient, though absolute numbers remain constrained by national population size.
Switzerland’s start-up process is generally efficient once the Swiss-specific regulatory requirements are understood and properly prepared for. The main risk of delay is under-preparation for Swiss requirements by sponsors accustomed to the EU CTR process. Typical ranges:
| Activity | Estimated Duration |
|---|---|
| Swissmedic and cantonal EC review (parallel) | 30–45 days |
| Site contract and budget negotiation | 6–12 weeks |
| Swiss sponsor representative setup (if required) | 4–8 weeks (one-time) |
| Site initiation visit and staff training | 2–3 weeks |
| First patient screened | ~3–5 months from submission |
Sponsors new to Switzerland should budget time for the one-time setup of Swiss regulatory infrastructure, including sponsor representation, Swiss-specific CTA documentation, and BASEC platform registration. Once this infrastructure is in place, subsequent Swiss submissions are more efficient.
Switzerland is the most expensive country in this group for clinical research. Swiss salary levels are substantially higher than in any EU country, and hospital overhead charges at Swiss university hospitals are among the highest in the world. Per-patient costs for a Phase II oncology trial typically range from €28,000 to €60,000, and can exceed this range for complex early-phase studies.
Additional costs specific to Switzerland include: Swiss regulatory fees (Swissmedic), Swiss sponsor representative fees (if applicable), multilingual document preparation (German/French/Italian depending on the site), and Swiss-specific GCP compliance overhead. Sponsors must justify Swiss inclusion on scientific or strategic grounds that outweigh these costs.
Switzerland is the right choice when its specific advantages cannot be replicated elsewhere. Sponsors should include Switzerland when:
Switzerland is not the right choice for cost-sensitive programmes, for trials where EU-only regulatory pathways are preferred, or for large Phase III trials that need high patient volumes.
APICES provides full-service CRO support for clinical trials in Switzerland, including Swissmedic regulatory submissions, cantonal ethics committee liaison via BASEC, Swiss sponsor representative services, site identification, and site management. Our team understands the Swiss-specific regulatory requirements that differ from the EU CTR framework and can guide sponsors through the category assessment, submission, and authorisation process.
For sponsors running programmes that combine Switzerland with EU countries, APICES manages the Swiss track as a parallel, independent process alongside the CTIS submission. We ensure that Swiss-specific requirements – Swiss GCP adaptations, local language patient documents, and Swissmedic reporting obligations – are met throughout the trial lifecycle without disrupting the broader European programme.
Does Switzerland use CTIS for clinical trial applications?
No – and this is the single most important regulatory fact for sponsors considering Switzerland. Switzerland is not a member of the EU or EEA and does not participate in the Clinical Trials Information System (CTIS) or the EU Clinical Trials Regulation (EU CTR, Regulation EU 536/2014). Clinical trials in Switzerland are governed entirely by Swiss national law: the Human Research Act (HRA, Humanforschungsgesetz, SR 810.30) and the Clinical Trials Ordinance (ClinO, Verordnung über klinische Versuche in der Humanforschung, SR 810.305). Swissmedic is the competent authority and cantonal ethics committees conduct the ethics review. Sponsors adding Switzerland to an EU programme must manage the Swiss regulatory submission as a completely separate track running in parallel with CTIS.
What is the approval process for clinical trials in Switzerland?
Swiss clinical trial applications are submitted via the BASEC online platform (managed by swissethics). For Category B and C trials, the submission goes simultaneously to the lead cantonal ethics committee and to Swissmedic. Both reviews typically run in parallel and conclude within 30–40 days (Swissmedic) and 30–45 days (cantonal ethics committee) respectively for well-prepared, complete dossiers. Category A trials – those involving authorised medicinal products used within the approved indication at authorised doses – require only cantonal ethics committee notification and do not require Swissmedic authorisation. Sponsors should determine the correct category for their trial early in the planning phase, as this fundamentally affects the regulatory pathway.
What are the trial categories under Swiss law?
Swiss law classifies clinical trials into three categories under the ClinO. Category A covers low-risk trials using authorised products within their approved indication; these require only ethics notification, not Swissmedic authorisation. Category B covers the majority of interventional clinical trials, including trials with authorised products outside their approved indication, unapproved IMPs, and most Phase II–III industry-sponsored trials; Swissmedic authorisation and cantonal EC approval are both required. Category C covers trials with a higher risk profile, including certain gene therapy trials, ATMPs, and trials in vulnerable populations with unapproved products; enhanced scrutiny from both Swissmedic and the cantonal ethics committee applies. Correct categorisation is the sponsor’s responsibility and should be confirmed with Swissmedic before submission.
What are the main clinical trial sites in Switzerland?
Switzerland’s five university hospital networks are the primary trial sites: University Hospital Zurich (USZ) – the largest and most active site, strong in oncology, neurology, and Phase I; University Hospital Basel (USB) – located in Switzerland’s pharma capital, with close industry relationships and strong oncology and haematology programmes; Inselspital Bern – strong in oncology, cardiovascular, and neurology; CHUV Lausanne – French-speaking Switzerland’s academic hospital, affiliated with the Ludwig Institute for Cancer Research, with exceptional oncology and immunology output; and HUG Geneva – internationally renowned for infectious disease, HIV, and rare disease research. All sites have dedicated clinical trial units with English-proficient research teams experienced in international industry-sponsored studies.
How expensive are clinical trials in Switzerland?
Switzerland is the most expensive country in this group for clinical research and among the most expensive in the world. Per-patient costs for a Phase II oncology trial typically range from €28,000 to €60,000. Swiss salary levels for research nurses, coordinators, and investigators exceed those in all EU countries, and hospital infrastructure costs are substantial. Additional Switzerland-specific costs include Swissmedic fees, multilingual document preparation (German, French, or Italian depending on the site), Swiss sponsor representative fees if required, and Swiss GCP compliance overhead. Sponsors must have a clear scientific or strategic justification that outweighs these costs before including Switzerland.
Does a non-Swiss sponsor need a Swiss representative?
Yes, in most cases. The ClinO requires that the sponsor have a registered address in Switzerland or designate an authorised Swiss representative (Prüfer) who assumes legal responsibility for the trial under Swiss law. For non-Swiss sponsors without Swiss operations, engaging a Swiss-based CRO, contract research site, or dedicated sponsor representative service to fulfil this requirement is standard practice. This setup should be arranged well before the BASEC submission is filed, as it affects the administrative documentation included in the application. APICES can assist sponsors in establishing Swiss sponsor representation as part of the trial setup process.
Get the latest clinical insights delivered to your feed or inbox!
Key Takeaways: First-in-human trials in the EU are governed by Regulation (EU) No 536/2014 and the EMA’s first-in-human guideline (EMEA/CHMP/SWP/28367/07 Rev 1). Sponsors must submit a complete Clinical Trial Application via the CTIS portal and obtain both Part I...
Key Takeaways: Phase I dose escalation design in the EU is governed by ICH E8(R1), EMA first-in-human guidance (EMA/CHMP/SWP/28367/07 Rev.1), and EU Clinical Trial Regulation 536/2014 via CTIS. The classical 3+3 design is increasingly replaced by model-based...
EU MDR clinical investigation requirements have fundamentally changed how Medtech sponsors plan and execute device studies in Europe. Regulation (EU) 2017/745 replaced the clinical investigation provisions of Directive 93/42/EEC (MDD) and introduced a more stringent, harmonised framework across all 27 EU member states. For sponsors running investigations in Spain, Germany, France, the Netherlands, or any other member state, understanding which pathway applies to their study is the single most consequential regulatory decision before CIP submission.
